Exubera May Be Wild Card In Sanofi Bid For Aventis; Genta Deal Unaffected

Aventis' share of the Phase III inhaled insulin Exubera is one of the wild cards that could come into play as a result of Sanofi's hostile takeover bid for the company

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet